Considerations for Novel COVID-19 Mucosal Vaccine Development
Mucosal surfaces are the first contact sites of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most SARS-CoV-2 vaccines induce specific IgG responses but provide limited mucosal immunity. Cytokine B-cell activation factor (BAFF) and A proliferation-inducing ligand (APRIL) in the t...
| Published in: | Vaccines |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1173 |